Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics, Inc. filed an automatic shelf registration on Form S-3 that registers for resale 29,474,569 shares of common stock and shares issuable upon exercise of pre-funded warrants to purchase up to 4,210,527 shares, related to a $160.0 million private placement closed March 9, 2026; the registration was declared effective on April 9, 2026.
The base prospectus also registers a variety of other equity and equity-linked securities (common stock, preferred stock, warrants, subscription rights, depositary shares, purchase contracts and units) for future offerings from time to time. Net proceeds from the private placement are stated to be used for working capital and general corporate purposes, including advancement of R&D for NDV-01 and Sepranolone development programs.
Relmada Therapeutics, Inc. ownership disclosure: Adage Capital Management, L.P. reports beneficial ownership of 4,763,158 shares of Common Stock, representing 4.54% of the class. The percentage is calculated using 104,890,223 shares outstanding as of March 16, 2026. The stake is held directly by Adage Capital Partners, L.P., with reporting by Adage Capital Management, L.P., and tied to the roles of Robert Atchinson and Phillip Gross as managing members of the relevant Adage entities.
Relmada Therapeutics reported a first quarter 2026 net loss of $19.1M, with operating expenses of $19.5M. Research and development was $8.1M and general and administrative expenses were $11.4M.
After a $160M PIPE financing that generated roughly $150M in net proceeds, cash, cash equivalents and short-term investments rose to $235.3M as of March 31, 2026, and management states this should fund operations through 2029. Common shares outstanding increased to 104.9 million.
The company highlighted Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, showing a 95% anytime complete response rate and 76% 12‑month complete response rate among 38 efficacy-evaluable patients, with no progressions to muscle-invasive disease or cystectomies reported. A BCG-unresponsive subgroup showed similar durability. Safety appeared manageable, with no grade 3 or higher treatment-related adverse events and no treatment discontinuations for safety.
Relmada has written FDA feedback supporting two registrational pathways for NDV-01 and plans to initiate the Phase 3 RESCUE program and a Phase 2 study of sepranolone in Prader‑Willi syndrome in mid‑2026. A provisional NDV‑01 patent filing could support protection into 2047.
Relmada Therapeutics reported a Q1 2026 net loss of $19,051,956, slightly higher than the prior-year loss of $17,559,465, as it continued investing in its clinical pipeline. Research and development expense fell to $8.1 million, while general and administrative expense rose to $11.4 million.
The company strengthened its balance sheet with a March 2026 private placement that raised approximately $150 million in net proceeds, lifting cash and short-term investments to about $233.9 million and total assets to $235.4 million as of March 31, 2026. Management believes this will fund operations for at least 12 months.
Relmada’s strategy now centers on NDV-01 for non-muscle invasive bladder cancer and sepranolone for Prader-Willi syndrome and other GABA-related disorders, following termination of its esmethadone and psilocybin programs. The company plans to start Phase 3 trials for NDV-01 and a Phase 2 study for sepranolone in mid-2026.
Relmada Therapeutics reports beneficial ownership by Commodore Capital entities of 5,505,527 shares as of April 27, 2026. This total consists of 1,295,000 shares held and 4,210,527 shares issuable upon exercise of a Pre-Funded Warrant. The filing cites 104,890,223 shares outstanding as of March 16, 2026, implying a 5.1% stake based on that figure.
Relmada Therapeutics presents its 2026 annual meeting agenda and details a sharp 2025 turnaround after its prior lead program failed. The company shifted strategy to acquire de‑risked assets, adding NDV‑01 for non‑muscle invasive bladder cancer and sepranolone for Prader‑Willi syndrome and other uses.
Management highlights a share price recovery from $0.24 (about $7 million market cap) to $4.83 (about $353 million) and cash growth to about $100 million after a November financing. Stockholders will vote on re‑electing two directors, ratifying the auditor, adding 3.0 million shares to the 2021 equity plan, and increasing authorized common stock from 150,000,000 to 200,000,000.
Relmada Therapeutics, Inc. registers 33,685,096 shares of common stock for resale by selling stockholders pursuant to a registration statement covering (i) 29,474,569 shares issued in a Private Placement and (ii) 4,210,527 shares issuable upon exercise of pre-funded warrants.
The prospectus states the company will receive no proceeds from resales under this registration; proceeds from any exercise of the Pre-Funded Warrants would be received by the company. Shares outstanding were 104,888,233 as of March 20, 2026. The resale may occur through a variety of methods at varying prices, and the Registration Rights Agreement requires the company to use commercially reasonable efforts to cause the registration statement to become effective within the agreed timeframes.
Relmada Therapeutics (RLMD) is asking shareholders to elect two directors and approve routine housekeeping proposals while describing a strategic turnaround completed in 2025. Management reports two clinical-stage acquisitions (NDV-01 and sepranolone), a successful $100 million financing in November, and a recovery in market value from a low of $0.24 to a post-financing high of $4.83.
The company reports cash increasing to approximately $100 million after the financing, retention and strengthening of its core team, planned Phase 2 and Phase 3 milestones for NDV-01 and sepranolone in mid-2026, and seeks shareholder approval to increase equity plan reserves by 3.0 million shares and authorized common shares from 150,000,000 to 200,000,000.
Relmada Therapeutics, Inc. filed a preliminary prospectus on a registration statement to register the resale of 33,685,096 shares of common stock, consisting of 29,474,569 issued shares and 4,210,527 shares underlying pre-funded warrants issued in a private placement. The shares are being registered for resale by the selling stockholders and the company will not receive proceeds from those resales. The private placement closed March 11, 2026 for aggregate gross proceeds of approximately $160.0 million (shares at $4.75 and pre-funded warrants at $4.749). Shares outstanding were 104,888,233 as of March 20, 2026; the last reported sale price was $6.99 per share on April 2, 2026.